Table 2. PVI and FCV of PDGFR-β as prognostic factors for overall survival in multivariate analyses in patients with mCRC (NORDIC-VII cohort, n=158).
| PVI | FCV | |||
|---|---|---|---|---|
| variable | HR (95% CI) | P value | HR (95% CI) | P value |
| PDGFR-β (low vs. high) | 1.78 (1.14-2.78) |
0.011 | 1.79 (1.16-2.76) |
0.009 |
| Vessel density (low vs. high) | 1.80 (1.16-2.78) |
0.009 | 1.90 (1.23-2.90) |
0.004 |
| Alkaline Phosphatase (elevated vs. normal) | 1.85 (1.20-2.84) |
0.005 | 1.89 (1.23-2.90) |
0.004 |
| Performance status (1, 2 vs. 0) | 1.67 (1.07-2.61) |
0.023 | 1.65 (1.06-2.56) |
0.027 |
| BRAF (mut vs. wt) | 4.48 (2.21-10.00) |
<0.001 | 4.50 (2.23-9.07) |
<0.001 |
Abbreviations: HR, hazard ratio; CI, confidence interval; mut, mutant; wt, wild type.